Alison Kraigsley | Program Officer, TB Vaccines
The Bill & Melinda Gates Foundation

Alison Kraigsley, Program Officer, TB Vaccines, The Bill & Melinda Gates Foundation

Alison Kraigsley is the TB Vaccines Program Officer at the Bill and Melinda Gates Foundation and is responsible for developing and managing a portfolio of research investments to address scientific gaps and support the development of a robust TB vaccine pipeline. Alison has a broad background in infectious disease research and policy. Prior to joining the BMGF, Alison was a researcher at the University of Minnesota Center for Infectious Disease Policy and Research (CIDRAP) where played a critical role in developing Influenza Vaccine Research and Development Roadmap ( The roadmap is a research agenda with a global perspective targeting the improvement of seasonal influenza vaccines and the development of new universal (or broadly protective) influenza vaccines. Additionally, she served as both an American Association for the Advancement of Science (AAAS) Science and Technology Policy Fellow and a Program Officer at the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID). During her time at NIAID, she supported programs in both tuberculosis and influenza. As an AAAS science and technology policy fellow, she supported the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS), a multi-university research network targeting influenza research, surveillance, and pandemic preparedness and served as an ex officio member of the ACIP Novel Influenza Vaccines Working Group. As a program officer in the NIAID Tuberculosis, Leprosy, and Other Mycobacterial Diseases section, Alison was responsible for the pathogen biology portfolio, as well as management of the multicenter Tuberculosis Research Units Network (TBRU-N). She served as an organizational consultant to the World Health Organization's Global TB Programme and the secretariat of the Mycobacterial Panel of the US-Japan Cooperative Medical Sciences Program. Alison earned a PhD in Molecular Biology and an MS in Aerospace Engineering from the University of Southern California and a BSc in Interdisciplinary Chemistry-Physics from Furman University.


WVIC/WAC Day 2 - Nov 30 @ 09:00

Global Health Goals – can we get back on track?

  • How has the pandemic affected the status of the epidemics of tuberculosis, malaria and neglected tropical diseases?
  • Silver linings – new investments in immunization infrastructure – understanding of barriers and opportunities in promoting vaccination within communities and countries. How do we try to capitalize on some of the new pathways generated because of covid?
  • How will malaria vaccines be implemented? How does this vaccine need to be promoted differently to previous vaccines? How to communicate value of vaccines in burdened communities. Integrated strategy required.
  • TB vaccines how are we moving forward? Next steps for TB vaccines.

WVIC/WAC Day 2 - Nov 30 @ 11:40

Panel: Research & development goals for influenza vaccines

  • What is the status of the influenza vaccine R&D landscape?
  • What areas of R&D are we focusing on to improve influenza vaccines?
  • Strategic goals for seasonal vs universal flu vaccines
  • Recent milestones achieved and gaps to address
  • What tools do we need to inform policy, and preparedness planning?
  • Pivoting to new manufacturing platforms to ensure faster response – what are the challenges
last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard

For sponsorship and exhibition opportunities:
Thomas Hall